Data from Genzyme’s Multiple Sclerosis Franchise Featured at AAN

Release Date:
Tuesday, April 22, 2014 8:00 am EDT

Terms:
Dateline City:
CAMBRIDGE, Mass.

- Aubagio® and Lemtrada™ Results To Be Highlighted -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 18 poster and oral presentations featuring Aubagio® (teriflunomide) and Lemtrada™ (alemtuzumab) will be presented during the 66th American Academy of Neurology (AAN) Annual Meeting to be held in Philadelphia, April 26 – May 3, 2014.

“As we continue to expand our global footprint in MS with product launches planned in more than 30 countries this year, we are proud to highlight the breadth and depth of our clinical development programs for Aubagio and Lemtrada at AAN,” said David Meeker, President and CEO, Genzyme. “These new data will help to build a deeper understanding of MS and Genzyme’s treatments, and demonstrate our long-term commitment to meeting the needs of people living with MS.”

Presentations on Aubagio and Lemtrada at AAN are as follows, along with information about the Genzyme Corporate Therapeutic Update and Brain Health Fair sponsorship.

Aubagio:
- TOPIC: Efficacy and Safety of Once-Daily Oral Teriflunomide in Patients with First Clinical Episode Consistent With Multiple Sclerosis (Clinical Trials Plenary Session; May 2; 12:00 – 1:30 p.m. EDT)
- Teriflunomide Does Not Significantly Affect Primary and Memory Antibody Responses to a Viral Antigen in Mice (Poster Session I – P1.215; April 28; 3:00 p.m. EDT)
- Teriflunomide Treatment Is Not Associated With Increased Risk of Infections: Pooled Data From the Teriflunomide Development Program (Poster Session II – P2.194; April 29; 7:30 a.m. EDT)
- Pooled Safety Data From Four Placebo-Controlled Teriflunomide Studies (Poster Session II – P2.203; April 29; 7:30 a.m. EDT)
- Teriflunomide: Non-Clinical Evaluation Demonstrates No Effect On Sperm DNA or Male Fertility (Poster Session II – P2.233; April 29; 7:30 a.m. EDT)
- Safety and Efficacy of Teriflunomide for up to 9 Years in Relapsing Forms of Multiple Sclerosis: Update of the TEMSO Extension Trial (Poster Session III – P3.150; April 29; 3:00 p.m. EDT)
- Patients Free of Clinical MS Activity in TEMSO and TOWER: Pooled Analyses of Two Phase 3 Placebo-Controlled Trials (Poster Session III – P3.164; April 29; 3:00 p.m. EDT)
- Updated Pregnancy Outcomes in Patients and Partners of Patients in the Teriflunomide Clinical Trial Program (Poster Session IV – P4.161; April 30; 7:30 a.m. EDT)
- Estimating the Onset of Efficacy With Teriflunomide in Patients With Relapsing Forms of Multiple Sclerosis (Poster Session VII – P7.214; May 1; 3:00 p.m. EDT)

Lemtrada:
- Treatment with Anti-mouse CD52 Antibody Is Associated with Preservation of Myelin and Maintenance of Axonal Conduction in the MOG-induced EAE Mouse Model (Poster Session I – P1.220; April 28; 3:00 p.m. EDT)
- Anti-murine CD52 Antibody Treatment Does Not Adversely Affect the Migratory Ability of Immune Cells (Poster Session I – P1.222; April 28; 3:00 p.m. EDT)
- Successful Detection and Management of Immune Thrombocytopenia in Alemtuzumab-Treated Patients with Active Relapsing-Remitting Multiple Sclerosis (Poster Session II - P2.198; April 29; 7:30 a.m. EDT)
- Thyroid Autoimmune Adverse Events in Patients Treated with Alemtuzumab for Relapsing-remitting Multiple Sclerosis: Four-year Follow-up of the CARE-MS Studies (Poster Session II – P2.199; April 29; 7:30 a.m. EDT)
- Safety of Using Disease-modifying Therapy Post-alemtuzumab Treatment in Patients With Relapsing-remitting Multiple Sclerosis in the Core and Extension Phases of CAMMS223, CARE-MS I, and CARE-MS II Studies (Poster Session II – P2.201; April 29; 7:30 a.m. EDT)
- Alemtuzumab Has Similar Efficacy and Safety in Active Relapsing-Remitting Multiple Sclerosis (RRMS) Patients Who
Alemuzumab Improves Visual Outcomes vs. Subcutaneous Interferon Beta-1a in Patients With Active Relapsing-Remitting Multiple Sclerosis (RRMS) Who Relapsed on Prior Therapy: Analysis From the CARE-MS II Study (Poster Session III – P3.158; April 29; 3:00 p.m. EDT; INS 7 Poster Rounds: Emerging Therapeutic Advances in Multiple Sclerosis – 17-1.010; April 30; 4:30 p.m. EDT)

Sustained Improvement in Disability Outcomes with Alemuzumab in Active Relapsing-Remitting Multiple Sclerosis Patients Who Participated in CARE-MS II: Three-year Follow-up (Poster Session III – P3.165; April 29; 3:00 p.m. EDT)

Lymphocyte Counts Do Not Predict Risk of Subsequent Relapse or Disability Accumulation in Alemuzumab-Treated Relapsing-Remitting Multiple Sclerosis Patients: An Analysis of the CARE-MS Studies (Poster Session III – P3.181; April 29; 3:00 p.m. EDT)

Abstracts are available on the AAN website.

**Genzyme Corporate Therapeutic Update**

**“The Evolving Paradigm: Individualizing MS Care”**

**When:** Tuesday, April 29; 7:00 – 8:30 p.m. EDT

**Location:** Sheraton Philadelphia Downtown Hotel, Liberty Ballroom (201 N 17th Street, Philadelphia)

**Brain Health Fair**

Genzyme is proud to serve as a silver sponsor of this year’s Brain Health Fair, taking place on Saturday, April 26. The Brain Health Fair, presented by the American Brain Foundation, the foundation of the American Academy of Neurology, is a free event that is open to the public and designed to help connect patients, families and caregivers affected by neurologic disorders.

**About Aubagio® (teriflunomide)**

Aubagio is approved in the United States, European Union, Australia, Argentina, Brazil, Canada, Chile, Columbia, Mexico, New Zealand, South Korea and Switzerland, with additional marketing applications under review by regulatory authorities globally.

Aubagio is an immunomodulator with anti-inflammatory properties. Although the exact mechanism of action for Aubagio is not fully understood, it may involve a reduction in the number of activated lymphocytes in the central nervous system (CNS). Aubagio is supported by one of the largest clinical programs of any MS therapy, with more than 5,000 trial participants in 36 countries. Some patients in extension trials have been treated for up to 10 years.

**About Lemtrada™ (alemuzumab)**

Lemtrada is approved in the European Union, Australia, Brazil, Canada and Mexico. Lemtrada is currently not approved in the United States. Following constructive discussions with the FDA, Genzyme plans to resubmit in the second quarter of 2014 its application seeking U.S. approval of Lemtrada. The resubmission will provide information to specifically address issues previously noted by the FDA in its December 2013 Complete Response Letter. Marketing applications for Lemtrada are also under review in other countries. Lemtrada is supported by a comprehensive and extensive clinical development program that involved nearly 1,500 patients and 5,400 patient-years of follow-up.

Alemuzumab is a monoclonal antibody that selectively targets CD52, a protein abundant on T and B cells. Treatment with alemuzumab results in the depletion of circulating T and B cells thought to be responsible for the damaging inflammatory process in MS. Alemuzumab has minimal impact on other immune cells. The acute anti-inflammatory effect of alemuzumab is immediately followed by the onset of a distinctive pattern of T and B cell repopulation that continues over time, rebalancing the immune system in a way that potentially reduces MS disease activity.

Genzyme holds the worldwide rights to alemuzumab and has primary responsibility for its development and commercialization in multiple sclerosis. Bayer HealthCare holds the right to co-promote alemuzumab in MS in the United States. Upon commercialization, Bayer will receive contingent payments based on global sales revenue.

**About Genzyme, a Sanofi Company**

Genzyme has pioneered the development and delivery of transformative therapies for patients affected by rare and debilitating diseases for over 30 years. We accomplish our goals through world-class research and with the compassion and commitment of our employees. With a focus on rare diseases and multiple sclerosis, we are dedicated to making a positive impact on the lives of the patients and families we serve. That goal guides and inspires us every day. Genzyme’s portfolio of transformative therapies, which are marketed in countries around the world, represents groundbreaking and life-saving advances in medicine. As a Sanofi company, Genzyme benefits from the reach and resources of one of the world’s largest pharmaceutical companies, with a shared commitment to improving the lives of patients. Learn more at www.genzyme.com.

Genzyme® and Aubagio® are registered trademarks and Lemtrada™ is a trademark of Genzyme Corporation.

**About Sanofi**

Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (Euronext: SAN) and in New York (NYSE: SNY).

**Sanofi Forward Looking Statements**
This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans” and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Statements” in Sanofi’s annual report on Form 20-F for the year ended December 31, 2013. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Language:
English

Contact:
Genzyme Media Relations
Erin Pascal, +1-617-768-6864
Erin.Pascal@genzyme.com
or
Sanofi Investor Relations
Kristen Galfetti, +1-908-981-5560
ir@sanofi.com

Ticker Slug:
Ticker: SAN
Exchange: BOURSE
ISIN: FR0000120578
Ticker: SNY
Exchange: NYSE
ISIN: US80105N1054